Cost-Effectiveness Analysis of Triple Therapy with Protease Inhibitors in Treatment-Naive Hepatitis C Patients

被引：0
|
作者：
Antonio Blázquez-Pérez
Ramón San Miguel
Javier Mar
机构：
[1] Agencia Española de Medicamentos y Productos Sanitarios,Departamento de Medicamentos de Uso Humano
[2] Complejo Hospitalario de Navarra,Department of Pharmacy
[3] Hospital Alto Deba,Clinical Management Service
来源：
PharmacoEconomics | 2013年 / 31卷
关键词：
Triple Therapy; Probabilistic Sensitivity Analysis; Dual Therapy; Telaprevir; Boceprevir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 931
页数：12
相关论文
共 50 条
  • [31] Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Sax, PE
    Islam, R
    Walensky, RP
    Losina, E
    Weinstein, MC
    Goldie, SJ
    Sadownik, SN
    Freedberg, KA
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 (09) : 1316 - 1323
  • [32] Treatment of chronic hepatitis C in treatment-naive patients
    Ferreira, Marcelo Simao
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 : 45 - 49
  • [33] Hepatitis C, disease and its management: a cost-effectiveness analysis of the new generation oral protease inhibitors
    Arshad, Mahreen
    Wei, Feifei
    Nelsen, David A., Jr.
    [J]. ANTIVIRAL THERAPY, 2015, 20 (08) : 827 - 833
  • [34] A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C
    Iannazzo, Sergio
    Colombatto, Piero
    Ricco, Gabriele
    Oliveri, Filippo
    Bonino, Ferruccio
    Brunetto, Maurizia R.
    [J]. DIGESTIVE AND LIVER DISEASE, 2015, 47 (03) : 249 - 254
  • [35] COST-EFFECTIVENESS ANA LYSIS OF SOFOSBUVIR BASED COMBINATION THERAPIES AMONG TREATMENT-NAIVE AND PRE-TREATED PATIENTS WITH HEPATITIS C INFECTION
    Gaitonde, P.
    Yerlikaya, N. S.
    Chirikov, V. V.
    Shaya, F. T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A236 - A236
  • [36] Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: a UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naive patients
    Gonzalez, Y. S.
    Ingram, A.
    Lindsay, C.
    Parise, H.
    Virabhak, S.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S747 - S748
  • [37] Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
    Fawsitt, Christopher G.
    Vickerman, Peter
    Cooke, Graham S.
    Welton, Nicky J.
    Barnes, Eleanor
    Ball, Jonathan
    Brainard, Diana
    Burgess, Gary
    Dillon, John
    Foster, Graham
    Gore, Charles
    Guha, Neil
    Halford, Rachel
    Whitby, Kevin
    Holmes, Chris
    Howe, Anita
    Hudson, Emma
    Hutchinson, Sharon
    Irving, William
    Khakoo, Salim
    Klenerman, Paul
    Martin, Natasha
    Massetto, Benedetta
    Mbisa, Tamyo
    McHutchison, John
    McKeating, Jane
    McLauchlan, John
    Miners, Alec
    Murray, Andrea
    Shaw, Peter
    Simmonds, Peter
    Spencer, Chris
    Thomson, Emma
    Zitzmann, Nicole
    [J]. VALUE IN HEALTH, 2020, 23 (02) : 180 - 190
  • [38] COST-EFFECTIVENESS OF PHARMACOTHERAPIES FOR TREATMENT NAIVE HEPATITIS C GENOTYPE 1 PATIENTS: A PAYER'S PERSPECTIVE
    Jalundhwala, Y. J.
    Manzoor, B. S.
    Patel, H.
    Cheng, W. H.
    Patel, P.
    Touchette, D. R.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [39] Cost-Effectiveness Assessment of Telaprevir Combination Treatment Compared to Pegylated-Interferon plus Ribavirin Alone in the Management of Chronic Hepatitis C in Treatment-naive Patients
    Brogan, Anita
    Miller, Jeffrey
    Talbird, Sandra
    Thompson, James
    Deniz, Baris
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S410 - S410
  • [40] Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada
    Despiégel N.
    Anger D.
    Martin M.
    Monga N.
    Cui Q.
    Rocchi A.
    Pulgar S.
    Gilchrist K.
    Refoios Camejo R.
    [J]. Infectious Diseases and Therapy, 2015, 4 (3) : 337 - 353
12345